Journal for ImmunoTherapy of Cancer (Nov 2023)
268 Development of FT825/ONO-8250: an off-the-shelf CAR-T cell with preferential HER2 targeting and engineered to enable multi-antigen targeting, improve trafficking, and overcome immunosuppression
- Tom Lee,
- Martin Hosking,
- Yijia Pan,
- Shohreh Sikaroodi,
- Lauren Fong,
- Bahram Valamehr,
- Soheila Shirinbak,
- Angela Gentile,
- Samad Ibitokou,
- Susumu Yamamoto,
- Eigen Peralta,
- Lorraine Loter,
- Laura Chow,
- Peter Szabo,
- Xu Yuan,
- Nicholas Brookhouser,
- Raedun Clarke,
- Kyla Omilusik,
- Shilpi Chandra,
- Stephanie Kennedy,
- Chris Ecker,
- Loraine Campanati,
- Karina Palomares,
- Mika K Kaneko,
- Tatsuo Maeda,
- Daisuke Nakayama,
- Betsy Rezner,
- Ramzey Abujarour,
- Yukinari Kato
Affiliations
- Tom Lee
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Martin Hosking
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Yijia Pan
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Shohreh Sikaroodi
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Lauren Fong
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Bahram Valamehr
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Soheila Shirinbak
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Angela Gentile
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Samad Ibitokou
- Poseida, San Diego, CA, USA
- Susumu Yamamoto
- 3 ONO Pharmaceutical co., ltd., Mishima-Gun, Osaka, Japan
- Eigen Peralta
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Lorraine Loter
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Laura Chow
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Peter Szabo
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Xu Yuan
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Nicholas Brookhouser
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Raedun Clarke
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Kyla Omilusik
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Shilpi Chandra
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Stephanie Kennedy
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Chris Ecker
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Loraine Campanati
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Karina Palomares
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Mika K Kaneko
- 2 Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
- Tatsuo Maeda
- 3 ONO Pharmaceutical co., ltd., Mishima-Gun, Osaka, Japan
- Daisuke Nakayama
- 3 ONO Pharmaceutical co., ltd., Mishima-Gun, Osaka, Japan
- Betsy Rezner
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Ramzey Abujarour
- 1Fate Therapeutics, Inc., San Diego, CA, USA
- Yukinari Kato
- 4 Toyoku University, Sendai, Japan
- DOI
- https://doi.org/10.1136/jitc-2023-SITC2023.0268
- Journal volume & issue
-
Vol. 11,
no. Suppl 1
Abstract
No abstracts available.